financetom
Business
financetom
/
Business
/
Protara Therapeutics Closes $75 Million Public Offering
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Protara Therapeutics Closes $75 Million Public Offering
Mar 10, 2026 9:51 PM

04:34 PM EST, 12/08/2025 (MT Newswires) -- Protara Therapeutics ( TARA ) said late Monday it has closed an underwritten public offering of about 13 million shares at $5.75 per share, for gross proceeds of roughly $75 million.

Underwriters were given a 30-day option to buy up to about 1.96 million additional shares, the company said.

Net proceeds will be used for its clinical programs, working capital and general corporate purposes, the clinical-stage company said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Protara Therapeutics Closes $75 Million Public Offering
Protara Therapeutics Closes $75 Million Public Offering
Mar 10, 2026
04:34 PM EST, 12/08/2025 (MT Newswires) -- Protara Therapeutics ( TARA ) said late Monday it has closed an underwritten public offering of about 13 million shares at $5.75 per share, for gross proceeds of roughly $75 million. Underwriters were given a 30-day option to buy up to about 1.96 million additional shares, the company said. Net proceeds will be...
Sei Investments Insider Sold Shares Worth $973,320, According to a Recent SEC Filing
Sei Investments Insider Sold Shares Worth $973,320, According to a Recent SEC Filing
Mar 10, 2026
04:33 PM EST, 12/08/2025 (MT Newswires) -- Philip McCabe, Executive Vice President and Head of SEI's Investment Management Business, on December 04, 2025, sold 12,000 shares in Sei Investments ( SEIC ) for $973,320. Following the Form 4 filing with the SEC, McCabe has control over a total of 64,986 common shares of the company, with 62,544 shares held directly...
Assembly Biosciences Reports Interim Phase 1b Data Showing Reductions in HSV-2 Shedding and Lesion Rates
Assembly Biosciences Reports Interim Phase 1b Data Showing Reductions in HSV-2 Shedding and Lesion Rates
Mar 10, 2026
04:32 PM EST, 12/08/2025 (MT Newswires) -- Assembly Biosciences ( ASMB ) said Monday interim Phase 1b results showed its weekly oral candidate ABI-1179 cut HSV-2 shedding by 98% and virologically confirmed genital lesion rates 91% versus placebo. The company said its monthly oral ABI-5366 regimen reduced Herpes Simplex Virus-2 shedding by 76% and virologically confirmed lesion rates by 88%....
Dyne Therapeutics Launches $300 Million Public Offering; Shares Drop After Hours
Dyne Therapeutics Launches $300 Million Public Offering; Shares Drop After Hours
Mar 10, 2026
04:32 PM EST, 12/08/2025 (MT Newswires) -- Dyne Therapeutics ( DYN ) commenced an underwritten public offering of $300 million of common stock. Underwriters have a 30-day option to buy up to an additional $45 million in shares, the company said Monday in a statement. Dyne shares fell 5.4% in after-hours trading. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved